Selected Publications
Tokarsky EJ, Crow JC, Guenther LM, Sherman J, Taslim C, Alexe G, Pishas KI, Rask G, Justis BS, Kasumova A, Stegmaier K, Lessnick SL, Theisen ER. Mitochondrial Dysfunction Is a Driver of SP-2509 Drug Resistance in Ewing Sarcoma. Mol Cancer Res Jul 6;20(7):1035-1046, 2022. PMID: 35298000
Dharia NV, Kugener G, Guenther LM, Malone CF, Durbin AD, Hong AL, Howard TP, Bandopadhayay P, Wechsler CS, Fung I, Warren AC, Dempster JM, Krill-Burger JM, Paolella BR, Moh P, Jha N, Tang A, Montgomery P, Boehm JS, Hahn WC, Roberts CWM, McFarland JM, Tsherniak A, Golub TR, Vazquez F, Stegmaier K. A First-Generation Pediatric Cancer Dependency Map. Nat Genet Apr; 53(4):529-538, 2021. PMID: 33753930
Chen S, Guenther LM, Aronhalt A, Cardillo L, Janeway KA, Church A. PD-1 and PD-L1 Expression 5 in Osteosarcoma: Which Specimen to Evaluate? J Pediatr Hematol Oncol Nov; 42(8):482-487, 2020. PMID: 31842180
Guenther LM, Dharia NV, Ross L, Conway A, Robichaud AL, Catlett JL 2nd, Wechsler CS, Frank ES, Goodale A, Church AJ, Tseng YY, Guha R, McKnight CG, Janeway KA, Boehm JS, Mora J, Davis MI, Alexe G, Piccioni F, Stegmaier K. A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing sarcoma. Clin Cancer Res Feb 15;25(4):1343-1357, 2019. PMID: 30397176
Guenther LM, Rowe RG, Acharya PT, Swenson DW, Meyer SC, Clinton CM, Guo D, Sridharan M, London WB, Grier HE, Ecklund K, Janeway KA. Response Evaluation Criteria in Solid Tumors (RECIST) Following Neoadjuvant Chemotherapy in Osteosarcoma. Pediatr Blood Cancer Apr;65(4):1-6, 2018, PMID: 29251406
Wan X, Kim SY, Guenther LM, Mendoza A, Briggs J, Yeung C, Currier D, Zhang H, Li WJ, Tuan RS, Deyrup AT, Khanna C, Helman L. Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrin. Oncogene 28(38):3401-11, 2009. PMID: 19597468
Last update: October 2022